Back to Search Start Over

Variability in pharmacologically-induced coma for treatment of refractory status epilepticus

Authors :
Institute for Medical Engineering and Science
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Picower Institute for Learning and Memory
An, Jingzhi
Purdon, Patrick L.
Brown, Emery Neal
Westover, M Brandon
Jonnalagadda, Durga
Moura, Valdery
Institute for Medical Engineering and Science
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Picower Institute for Learning and Memory
An, Jingzhi
Purdon, Patrick L.
Brown, Emery Neal
Westover, M Brandon
Jonnalagadda, Durga
Moura, Valdery
Source :
PLoS
Publication Year :
2019

Abstract

Objective To characterize the amount of EEG suppression achieved in refractory status epilepticus (RSE) patients treated with pharmacologically-induced coma (PIC). Methods We analyzed EEG recordings from 35 RSE patients between 21-84 years-old who received PIC that target burst suppression and quantified the amount of EEG suppression using the burst suppression probability (BSP). Then we measured the variability of BSPs with respect to a reference level of BSP 0.8 ± 0.15. Finally, we also measured the variability of BSPs with respect to the amount of intravenous anesthetic drugs (IVADs) received by the patients. Results Patients remained in the reference BSP range for only 8% (median, interquartile range IQR [0, 29] %) of the total time under treatment. The median time with BSP below the reference range was 84% (IQR [37, 100] %). BSPs in some patients drifted significantly over time despite constant infusion rates of IVADs. Similar weight-normalized infusion rates of IVADs in different patients nearly always resulted in distinct BSPs (probability 0.93 (IQR [0.82, 1.0]). Conclusion This study quantitatively identified high variability in the amount of EEG suppression achieved in clinical practice when treating RSE patients. While some of this variability may arise from clinicians purposefully deviating from clinical practice guidelines, our results show that the high variability also arises in part from significant inter- and intra-individual pharmacokinetic/ pharmacodynamic variation. Our results indicate that the delicate balance between maintaining sufficient EEG suppression in RSE patients and minimizing IVAD exposure in clinical practice is challenging to achieve. This may affect patient outcomes and confound studies seeking to determine an optimal amount of EEG suppression for treatment of RSE. Therefore, our analysis points to the need for developing an alternative paradigm, such as vigilant anesthetic management as happens in operating rooms, or closed-loop a<br />National Institute of Neurological Disorders and Stroke (U.S.) (1K23NS090900)<br />Guggenheim Fellowship in Applied Mathematics<br />National Institutes of Health (U.S.) (Transformative Research Award R01-GM104 948)<br />Massachusetts General Hospital

Details

Database :
OAIster
Journal :
PLoS
Notes :
application/pdf
Publication Type :
Electronic Resource
Accession number :
edsoai.on1088511687
Document Type :
Electronic Resource